Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: Not so easy

Journal of Clinical Oncology

Volumn 28, Issue 4, 2010, Pages 519-521

  Bosl, George J ^a   Motzer, Robert J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CARDIOVASCULAR DISEASE; COLON CANCER; DISEASE FREE SURVIVAL; EDITORIAL; HUMAN; LEUKEMIA; LYMPH NODE DISSECTION; METASTASIS; MINIMAL RESIDUAL DISEASE; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TERATOMA; TREATMENT OUTCOME; TUMOR VOLUME; LYMPHADENECTOMY; MALE; NOTE; RETROPERITONEUM; TESTIS TUMOR; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM RECURRENCE, LOCAL; RETROPERITONEAL SPACE; TESTICULAR NEOPLASMS;

EID: 77449154935     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.0738     Document Type: Editorial

References (31)

1. Toner GC, Panicek DM, Heelan RT, et al: Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection. J Clin Oncol 8:1683-1694, 1990
2. Beck SD, Foster RS, Bihrle R, et al: Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. J Urol 168:1402-1404, 2002 (Pubitemid 35034131)
3. Steyerberg EW, Keizer HJ, Fo̊ssa SD, et al: Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups. J Clin Oncol 13:1177-1187, 1995
4. Oldenburg J, Alfsen GC, Lien HH, et al: Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 21:3310-3317, 2003 (Pubitemid 46606265)
5. Donohue JP, Rowland RG, Kopecky K, et al: Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis tumor. J Urol 137:1176-1179, 1987
6. Ehrlich Y, Brames MJ, Beck SDW, et al: Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: Is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 28:531-536, 2010
7. Kollmannsberger C, Daneshmand S, So A, et al: Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol 28:537-542, 2010
8. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers - International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594-603, 1997
9. Carver BS, Shayegan B, Eggener S, et al: Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 25:4365-4369, 2007 (Pubitemid 350013841)
10. Dash A, Carver BS, Stasi J, et al: The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. Cancer 112:800-805, 2008
11. Carver BS, Serio AM, Bajorin D, et al: Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol 25:5603-5608, 2007
12. Pettus JA, Carver BS, Masterson T, et al: Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology 73:328-331, 2009; discussion 331-332
13. Mosharafa AA, Foster RS, Koch MO, et al: Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol 171:1839-1841, 2004
14. Rodriguez E, Mathew S, Reuter V, et al: Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res 52:2285-2291, 1992
15. Bosl G: Significant differences in Ki67, P53 expression and apoptosis characterize germ cell tumor (GCT) differentiation and progression. Proc Am Soc Clin Oncol 19:660A, 2000
16. George DW, Foster RS, Hromas RA, et al: Update on late relapse of germ cell tumor: A clinical and molecular analysis. J Clin Oncol 21:113-122, 2003
17. Oldenburg J, Alfsen GC, Waehre H, et al: Late recurrences of germ cell malignancies: A population-based experience over three decades. Br J Cancer 94:820-827, 2006
18. Ronnen EA, Kondagunta GV, Bacik J, et al: Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol 23:6999-7004, 2005 (Pubitemid 46260286)
19. Gerl A, Clemm C, Schmeller N, et al: Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8:41-47, 1997 (Pubitemid 27112801)
20. Mettler FA Jr, Huda W, Yoshizumi TT, et al: Effective doses in radiology and diagnostic nuclear medicine: A catalog. Radiology 248:254-263, 2008
21. Health Physics Society fact sheet: Radiation exposure from medical diagnostic imaging procedures. http://www.hps.org/documents/meddiagimaging.pdf
22. Oechsle K, Hartmann M, Brenner W, et al: [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: The German multicenter positron emission tomography study group. J Clin Oncol 26:5930-5935, 2008
23. Brenner DJ, Doll R, Goodhead DT, et al: Cancer risks attributable to low doses of ionizing radiation: Assessing what we really know. Proc Natl Acad Sci U S A 100:13761-13766, 2003
24. Preston DL, Ron E, Tokuoka S, et al: Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 168:1-64, 2007
25. Morin Doody M, Lonstein JE, Stovall M, et al: Breast cancer mortality after diagnostic radiography: Findings from the U.S. Scoliosis Cohort Study. Spine (Phila Pa 1976) 25:2052-2063, 2000
26. Brenner DJ, Hall EJ: Computed tomography: An increasing source of radiation exposure. N Engl J Med 357:2277-2284, 2007 (Pubitemid 350190758)
27. Dauer LT, St Germain J, Meyers PA: Let's image gently: Reducing excessive reliance on CT scans. Pediatr Blood Cancer 51:838, 2008
28. Chamie K, Kurzrock EA, Romero V, et al: Increased risk of secondary malignancy in patients on active surveillance for NSGCT. J Urol 179:172-173, 2008 (suppl; abstr 492)
29. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al: Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370-4378, 2007
30. Feldman DR, Bosl GJ, Sheinfeld J, et al: Medical treatment of advanced testicular cancer. JAMA 299:672-684, 2008 (Pubitemid 351252727)
31. Feuer EJ, Sheinfeld J, Bosl GJ: Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. J Natl Cancer Inst 91:816-818, 1999 (Pubitemid 29252296)